{
    "2021-04-29": [
        [
            {
                "time": "",
                "original_text": "国盛证券维持泰格医药买入评级：业绩超预期，订单充足成长确定性强",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "业绩超预期",
                        "订单充足",
                        "成长确定性"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "群益证券给予泰格医药买进评级：Q1净利润同比增长79%，主业恢复显着,投资收益增厚净利润",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q1净利润",
                        "同比增长79%",
                        "主业恢复",
                        "投资收益"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "会议 | 大湾区(广州)生物医药创新者峰会",
                "features": {
                    "keywords": [
                        "大湾区",
                        "生物医药",
                        "创新者峰会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "这些讨论干货满满！决定中国创新药产业未来的核⼼竞争力是什么？",
                "features": {
                    "keywords": [
                        "创新药",
                        "核心竞争力",
                        "未来"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药一季度营利双涨，净利润同比增长178.62%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "一季度",
                        "营利双涨",
                        "净利润增长178.62%"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药(03347.HK)首季多赚79%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "首季",
                        "多赚79%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "港股盘前必读：港交所承认正研究SPAC上市机制最快在6月底前咨询市场",
                "features": {
                    "keywords": [
                        "港股",
                        "港交所",
                        "SPAC",
                        "上市机制",
                        "6月底前"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}